Pramlintide Acetate Injection — FDA Drug Shortage

To Be Discontinued — AstraZeneca AB

The FDA lists a drug shortage record for Pramlintide Acetate Injection (injection) from AstraZeneca AB with status To Be Discontinued. The shortage was first posted on 10/27/2025.

Shortage Details

Status
To Be Discontinued
Company
AstraZeneca AB
Package NDC
0310-6615-02
Dosage Form
Injection
Presentation
SymlinPen® 60 , Injection, 1000 ug/1 mL (NDC 0310-6615-02)
Initial Posting
10/27/2025
Revised Date